All In Biotech

Drug Trial Radar · NCT06832722

A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.

Multi-center, Randomized, Placebo-controlled, Double-blind Phase 1b/2a Trial to Investigate Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Invobenitug Also Known as Procizumab (PCZ; AK1967) in Patients With Cardiogenic Shock and Elevated Circulating Dipeptidyl Peptidase 3 (cDPP3) Concentrations.

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 13, 2025

Primary completion

Dec 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
4TEEN4 Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Feb 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this Phase 1b/2a trial is to evaluate the safety, tolerability, and exploratory efficacy of invobenitug (also known as procizumab), a monoclonal antibody under development for the treatment of cardiogenic shock (CS). CS is a life-threatening hypoperfusion of vital organs that frequently results in death. In addition to safety and tolerability, pharmacokinetics and pharmacodynamics of invobenitug are evaluated to define the optimum phase 2 dose (P2D) of invobenitug.

Conditions

  • Shock, Cardiogenic

Interventions

  • AK1967 (Invobenitug also known as Procizumab)Drug

    DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)

  • PlaceboDrug

    Application of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reported number of treatment-emergent adverse events from start of Invobenitug administration up until the last follow-up visit after Invobenitug administrationTime frame: 30 days

Locations

37 sites in 9 countries. Site status is shown where the registry gives one.

  • Yerevan medical scientific center

    Yerevan, Armenia · Not yet recruiting

  • Erebouni Mwdical Center

    Yerevan, Armenia · Not yet recruiting

  • Heart Center Aalst, AZORG

    Aalst, Belgium · Recruiting

  • University Hospital Saint Pierre

    Brussels, Belgium · Recruiting

  • Ghent University Hospital

    Ghent, Belgium · Not yet recruiting

  • University Hospital and Medical Faculty of Pilsen

    Pilsen, Czechia · Recruiting

  • Charles University Motol University Hospital

    Prague, Czechia · Recruiting

  • General University Hospital in Prague - FVN

    Prague, Czechia · Recruiting

  • Institute of Clinical and Experimental Medicine - IKEM

    Prague, Czechia · Recruiting

  • University Hospital Avicenne AP-HP

    Bobigny, France · Recruiting

  • Département d'anesthésie-réanimation

    Dijon, France · Not yet recruiting

  • University Hospital Lille - Institut Cœur Poumon

    Lille, France · Recruiting

  • University Hospital - Dupuytren Limoges

    Limoges, France · Recruiting

  • Regional University Hospital Nancy - Hopitaux de Brabois

    Nancy, France · Recruiting

  • Hôpital Pitié Salpêtrière

    Paris, France · Not yet recruiting

  • Lariboisière Hospital AP-HP

    Paris, France · Recruiting

  • Deutsches Herzzentrum der Charite (DHZC)

    Berlin, Germany · Not yet recruiting

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany · Not yet recruiting

  • University Medical Center Hamburg-Eppendorf

    Hamburg, Germany · Not yet recruiting

  • Herzzentrum Leipzig GmbH

    Leipzig, Germany · Not yet recruiting

  • Universitätsmedizin Mannheim

    Mannheim, Germany · Not yet recruiting

  • Radboud University Medical Center

    Nijmegen, Netherlands · Recruiting

  • Uniersytecki Szpital Kliniczny w Białystoku

    Bialystok, Poland · Recruiting

  • Górnośląskie Centrum Medyczne w Katowicach / Śląski Uniwersytet Medyczny w Katowicach

    Katowice, Poland · Recruiting

  • Clinical University Hospital Poznań

    Poznan, Poland · Recruiting

  • J. Mikulicz Radecki Clinical University Hospital Wrocław

    Wroclaw, Poland · Recruiting

  • Clinical Hospital Center Bezanijska Kosa

    Belgrade, Serbia · Not yet recruiting

  • Institute for Cardiovascular Diseases of Vojvodina

    Kamenitz, Serbia · Not yet recruiting

  • Clinical Center Niš

    Niš, Serbia · Not yet recruiting

  • Fundación Pública Galega de Investigación Biomédica INIBIC

    A Coruña, Spain · Not yet recruiting

  • Fundació Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Not yet recruiting

  • Fundació Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Not yet recruiting

  • Hospital Clinic de Barcelona

    Barcelona, Spain · Not yet recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain · Not yet recruiting

  • L'Hospitalet de Llobregat

    Barcelona, Spain · Not yet recruiting

  • Fundación para la Investigación Biomédica del Hospital Universitario La Paz

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario 12 De Octubre

    Madrid, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.